Mechanistic insights into insulin resistance in the genetic era

被引:29
作者
Parker, V. E. R. [1 ]
Savage, D. B. [1 ]
O'Rahilly, S. [1 ]
Semple, R. K. [1 ]
机构
[1] Univ Cambridge, Addenbrookes Hosp, Metab Res Labs, Inst Metab Sci, Cambridge CB2 0QQ, England
基金
英国医学研究理事会; 英国惠康基金;
关键词
diabetes; dyslipidaemia; genetics; insulin receptor; insulin resistance; PARTIAL LIPODYSTROPHY; PLASMA ADIPONECTIN; PPAR-GAMMA; BODY-FAT; RECEPTOR; DEFICIENCY; MUTATION; FEATURES; PATIENT; SUSCEPTIBILITY;
D O I
10.1111/j.1464-5491.2011.03463.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Sir Harold Himsworth first observed and articulated the phenomenon of insulin resistance in the late 1930s. Although a long delay followed before his observations were acknowledged and enshrined in formal diagnostic classifications of diabetes mellitus, insulin resistance-related pathology in the early 21st century poses one of the major global healthcare challenges for contemporary physicians. Whilst insulin resistance is closely related to obesity and decreased physical fitness, despite intensive investigation it has proved extremely challenging to discriminate key events in its causation from epiphenomena, many related to compensation for the primary defect. Thus, a complete account of the molecular pathogenesis of insulin resistance-related diseases remains elusive. One approach circumventing such problems is the study of patients with single gene defects causing severe insulin resistance. In such patients the primary defect is known, and thus lessons may be learned about human physiology from detailed physiological study allied to knowledge of the function of the mutated protein. This review discusses developments in understanding of monogenic severe insulin resistance since discovery of the first insulin receptor mutations in 1988 and reviews the physiological lessons learnt, including the critical role of adipose tissue in human metabolic health and the meaning and importance of partial insulin resistance for major human disease.
引用
收藏
页码:1476 / 1486
页数:11
相关论文
共 69 条
[1]   A novel heterozygous mutation in peroxisome proliferator-activated receptor-γ gene in a patient with familial partial lipodystrophy [J].
Agarwal, AK ;
Garg, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (01) :408-411
[2]   AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34 [J].
Agarwal, AK ;
Arioglu, E ;
de Almeida, S ;
Akkoc, N ;
Taylor, SI ;
Bowcock, AM ;
Barnes, RI ;
Garg, A .
NATURE GENETICS, 2002, 31 (01) :21-23
[3]  
Banting FG, 1922, CAN MED ASSOC J, V7, P141
[4]  
Bayliss WM, 1902, J PHYSIOL-LONDON, V28, P325
[5]   Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis [J].
Biddinger, Sudha B. ;
Hernandez-Ono, Antonio ;
Rask-Madsen, Christian ;
Haas, Joel T. ;
Aleman, Jose O. ;
Suzuki, Ryo ;
Scapa, Erez F. ;
Agarwal, Chhavi ;
Carey, Martin C. ;
Stephanopoulos, Gregory ;
Cohen, David E. ;
King, George L. ;
Ginsberg, Henry N. ;
Kahn, C. Ronald .
CELL METABOLISM, 2008, 7 (02) :125-134
[6]   Seipin deficiency alters fatty acid Δ9 desaturation and lipid droplet formation in Berardinelli-Seip congenital lipodystrophy [J].
Boutet, Emilie ;
El Mourabit, Haquima ;
Prot, Matthieu ;
Nemani, Mona ;
Khallouf, Eliane ;
Colard, Odile ;
Maurice, Michele ;
Durand-Schneider, Anne-Marie ;
Chretien, Yves ;
Gres, Sandra ;
Wolf, Claude ;
Saulnier-Blache, Jean-Sebastien ;
Capeaua, Jacqueline ;
Magre, Jocelyne .
BIOCHIMIE, 2009, 91 (06) :796-803
[7]   Selective versus total insulin resistance: A pathogenic paradox [J].
Brown, Michael S. ;
Goldstein, Joseph L. .
CELL METABOLISM, 2008, 7 (02) :95-96
[8]   A RECEPTOR-MEDIATED PATHWAY FOR CHOLESTEROL HOMEOSTASIS [J].
BROWN, MS ;
GOLDSTEIN, JL .
SCIENCE, 1986, 232 (4746) :34-47
[9]   The Human Lipodystrophy Gene Product Berardinelli-Seip Congenital Lipodystrophy 2/Seipin Plays a Key Role in Adipocyte Differentiation [J].
Chen, Weiqin ;
Yechoor, Vijay K. ;
Chang, Benny Hung-Junn ;
Li, Ming V. ;
March, Keith L. ;
Chan, Lawrence .
ENDOCRINOLOGY, 2009, 150 (10) :4552-4561
[10]   Efficacy of leptin therapy in the different forms of human lipodystrophy [J].
Chong, A. Y. ;
Lupsa, B. C. ;
Cochran, E. K. ;
Gorden, P. .
DIABETOLOGIA, 2010, 53 (01) :27-35